2020
Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.
Hu JK, Carlson K, Girardi M. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides. The Yale Journal Of Biology And Medicine 2020, 93: 41-44. PMID: 32226334, PMCID: PMC7087069.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMycosis fungoidesLocal immunotherapyIntralesional injectionSide effectsAssociated systemic side effectsSkin-homing T cellsEarly-stage mycosis fungoidesTreatment of MFCases of MFGeneralized side effectsStage mycosis fungoidesT-cell lymphomaSystemic side effectsRecombinant interferon α2bImprovement of diseaseSystemic therapyRecalcitrant lesionsMF patientsTherapeutic optionsMalignant CD4Intramuscular injectionMF lesionsSystemic administrationSubsequent dosing
2013
Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
Huang J, Cowper S, Moss J, Girardi M. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides. Journal Of Drugs In Dermatology 2013, 12: 487-9. PMID: 23652902.Peer-Reviewed Case Reports and Technical NotesConceptsExcimer laser therapyOral bexaroteneLaser therapyMycosis fungoides lesionsMinimal side effectsMF plaquesLocal erythemaMycosis fungoidesTreatment regimenCutaneous lesionsMF lesionsHistologic resolutionSide effectsTherapyBexaroteneLesionsUltraviolet ARegimenPUVAPatientsTreatmentPlaquesCase experienceFungoidesErythema
2010
A transient epidermolysis bullosa simplex‐like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygote
Trufant JW, Kreizenbeck GM, Carlson KR, Muthusamy V, Girardi M, Bosenberg MW. A transient epidermolysis bullosa simplex‐like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygote. Journal Of Cutaneous Pathology 2010, 37: 1155-1160. PMID: 20849457, DOI: 10.1111/j.1600-0560.2010.01557.x.Peer-Reviewed Original ResearchConceptsBexarotene treatmentEpidermolysis bullosa simplexKeratinocyte lysisCutaneous T-cell lymphomaT-cell lymphomaPalmoplantar keratodermaIntraepidermal blister formationClinical subtypesClinical trialsDrug treatmentSide effectsMechanobullous disordersReticulate hyperpigmentationSkin fragilityLike phenotypeKeratin 5Genetic sequencingSimilar frequencyRare variantsFocal palmoplantar keratodermaBlister formationTreatmentKRT5 mutationKeratin synthesisKeratoderma